72.76

6.49% -5.05

Pre-market: 72.75 -0.01 -0.01%

Kymera Therapeutics Inc (KYMR)

Overview News Price History Option Chain Financials Discussions Forecast

Kymera Therapeutics Inc stock is traded at $72.76, with a volume of 853.77K. It is down -6.49% in the last 24 hours and up +13.21% over the past month. Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Previous Close:

$77.81

Open:

$77.35

24h Volume:

853.77K

Relative Volume:

0.92

Market Cap:

$5.82B

Revenue:

$58.89M

Net Income/Loss:

$-240.88M

P/E Ratio:

-23.47

EPS:

-3.1

Net Cash Flow:

$-239.96M

1W Performance:

-10.53%

1M Performance:

+13.21%

6M Performance:

+63.40%

1Y Performance:

+77.94%

1-Day Range:

$72.16

$77.83

1-Week Range:

$72.16

$81.94

52-Week Range:

$19.45

$103.00

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name

Kymera Therapeutics Inc

Sector

Healthcare (1132)

Industry

Biotechnology (631)

Phone

857-285-5314

Address

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Employee

225

Twitter

Next Earnings Date

2025-08-01

Latest SEC Filings

KYMR's Discussions on Twitter

Compare KYMR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYMR Kymera Therapeutics Inc	72.76	6.22B	58.89M	-240.88M	-239.96M	-3.10
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-03-25	Resumed	Guggenheim	Buy
Oct-24-25	Reiterated	B. Riley Securities	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Sep-18-25	Reiterated	H.C. Wainwright	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-16-25	Initiated	RBC Capital Mkts	Outperform
Jul-30-25	Resumed	B. Riley Securities	Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy
May-20-25	Resumed	Stifel	Buy
Mar-13-25	Initiated	Citigroup	Buy
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Market Perform
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Overweight
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-22-24	Initiated	Oppenheimer	Outperform
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-30-23	Initiated	Truist	Buy
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy
Aug-03-22	Initiated	Goldman	Buy
Jul-20-22	Initiated	SVB Leerink	Mkt Perform
Apr-28-22	Initiated	Credit Suisse	Outperform
Mar-10-22	Initiated	JP Morgan	Neutral
Feb-10-22	Initiated	Wells Fargo	Overweight
Sep-30-21	Initiated	B. Riley Securities	Neutral
Sep-30-21	Initiated	Stifel	Buy
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral
May-21-21	Initiated	UBS	Buy
Apr-14-21	Initiated	Berenberg	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Sep-15-20	Initiated	BofA Securities	Neutral
Sep-15-20	Initiated	Cowen	Outperform
Sep-15-20	Initiated	Guggenheim	Buy
Sep-15-20	Initiated	Morgan Stanley	Equal-Weight

View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

Jan 04, 2026

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next - ts2.tech

Jan 04, 2026

Jan 03, 2026

KYMR Stock Falls -14% With A 7-day Losing Spree On Significant Insider Selling - Trefis

Jan 03, 2026

Jan 02, 2026

Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next - ts2.tech

Jan 02, 2026

The Technical Signals Behind (KYMR) That Institutions Follow - Stock Traders Daily

Jan 01, 2026

Dec 31, 2025

Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares - MarketBeat

Dec 31, 2025

Kymera Therapeutics Insider Sold Shares Worth $2,341,939, According to a Recent SEC Filing - marketscreener.com

Dec 31, 2025

Kymera Therapeutics (NASDAQ: KYMR) CEO reports option exercise and share sale - Stock Titan

Dec 31, 2025

Kymera Therapeutics Earnings Notes - Trefis

Dec 31, 2025

Dec 30, 2025

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching - ts2.tech

Dec 30, 2025

Dec 29, 2025

Kymera Therapeutics announces results from BroADen Phase 1b trial of KT-621 - MSN

Dec 29, 2025

Dec 28, 2025

Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN

Dec 28, 2025

Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN

Dec 28, 2025

Dec 22, 2025

B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq

Dec 22, 2025

Why Kymera Therapeutics Stock Is Sliding Despite Hype - TipRanks

Dec 22, 2025

KYMR: B. Riley Securities Raises Price Target for Kymera Therape - GuruFocus

Dec 22, 2025

B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating - marketscreener.com

Dec 22, 2025

Dec 20, 2025

Can Kymera Therapeutics Inc. stock hit analyst price targets2025 Valuation Update & Daily Growth Stock Tips - Улправда

Dec 20, 2025

Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Dec 20, 2025

Dec 19, 2025

What momentum indicators show for Kymera Therapeutics Inc. stockDividend Hike & Low Risk Entry Point Guides - ulpravda.ru

Dec 19, 2025

Dec 18, 2025

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 3.4%Here's What Happened - MarketBeat

Dec 18, 2025

Can Kymera Therapeutics Inc. stock deliver consistent earnings growth - Улправда

Dec 18, 2025

Kymera Therapeutics Insider Sold Shares Worth $2,264,480, According to a Recent SEC Filing - marketscreener.com

Dec 18, 2025

Dec 17, 2025

Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 24/7 Wall St.

Dec 17, 2025

Why Analysts See Kymera Therapeutics Differently After KT 621 Momentum And Rising Fair Value - Yahoo Finance

Dec 17, 2025

Dec 16, 2025

RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq

Dec 16, 2025

Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says - marketscreener.com

Dec 16, 2025

RBC Capital Raises Price Target for Kymera Therapeutics (KYMR) | - GuruFocus

Dec 16, 2025

RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk - marketscreener.com

Dec 16, 2025

Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital - Investing.com Canada

Dec 16, 2025

Kymera's eczema drug gets fast track designation in the United States - MSN

Dec 16, 2025

Obesity data, Kymera and FDA sentiment survey results — a BioCentury podcast - BioCentury

Dec 16, 2025

Dec 15, 2025

Kymera gains fast track status for oral candidate KT-621 for eczema - MSN

Dec 15, 2025

Kymera Therapeutics Insider Sold Shares Worth $21,699,044, According to a Recent SEC Filing - marketscreener.com

Dec 15, 2025

Dec 14, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Dec 14, 2025

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Barron's

Dec 14, 2025

Dec 13, 2025

Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares - MarketBeat

Dec 13, 2025

Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock - MarketBeat

Dec 13, 2025

Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares - MarketBeat

Dec 13, 2025

Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Dec 13, 2025

BVF Inc. IL Boosts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Dec 13, 2025

Dec 12, 2025

Kymera Therapeutics director Booth sells $21.7 million in stock By Investing.com - Investing.com Canada

Dec 12, 2025

Kymera Therapeutics director Booth sells $21.7 million in stock - Investing.com

Dec 12, 2025